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Abstract
Objectives: Patients with advanced stage colorectal carcinoma (CRC) display hepatic metastases on initial staging in
up to 20% of cases. The effectiveness of chemotherapy is generally evaluated by computed tomography (CT) imaging
using standardized criteria (RECIST). However, RECIST is not always optimal, and other criteria have been shown to
correlate with pathologic response and overall survival. The aim of this study was to evaluate the prognostic value of
different CT measurement for response assessment after initiation of chemotherapy in patients with synchronous
colorectal cancer liver metastases. Methods: Fifty-five patients with CRC and synchronous hepatic metastases were
evaluated retrospectively at 2 academic centers. Different size, volume, ratio and attenuation parameters were deter-
mined at baseline and after 3 cycles of chemotherapy. The prognostic value of baseline measurements and of the
change between baseline and second measurements was analyzed using KaplanMeier estimates. Results: Median
time to progression was 279 days, median overall survival was 704 days. In this selective patient population, neither a
significant prognostic value of initial baseline CT parameters nor a prognostic value of the change between the
first and the second CT measurements was found. Conclusion: Initial morphological response assessment using
different CT measurements has no prognostic value concerning time to progression or overall survival in patients
with synchronous colorectal liver metastases.
Keywords: CT measurement; colorectal cancer; prognosis; therapy response; tumor response.
Introduction
Cancer of the colon and rectum (CRC) is the third most
commonly diagnosed tumor type in men, and the second
most common type in women worldwide[1]. It represents
the second (in men) and third (in women) most common
cause of cancer-related death in developed countries[1,2].
Of all patients diagnosed, up to 20% have liver metastases
(CRC stage IV) on initial staging[2]. Only a minority of
these patients are eligible for curative resection[3].
Systemic chemotherapy without biological agents
offered a mean overall survival of 1220 months, and
5-year survival rates of less than 5%[4]. The introduction
of targeted agents such as bevacizumab and cetuximab in
combination with chemotherapy has led to an increase in
progression-free and overall survival (OS) rates in several
clinical studies[58], with median OS exceeding 2 years.
Patients receiving chemotherapy are closely monitored
by clinical course, laboratory parameters (e.g. tumor mar-
kers), and imaging. The evaluation of treatment response
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is usually done by computed tomography (CT) after 23
cycles of chemotherapy[9]. The current standard criteria
used to evaluate tumor response, the modified Response
Evaluation Criteria in Solid Tumors (RECIST 1.1)[10],
were developed to assess tumor shrinkage after cytotoxic
chemotherapy, and may be limited in assessing response
to biological agents, which exhibit a cytostatic mecha-
nism of action[11]. It has been recognized that there is
discordance between the World Health Organization
(WHO) criteria and RECIST guidelines[12]. RECIST
has also been shown to be of limited value, e.g. for ther-
apy response evaluation in gastrointestinal stroma tumors
(GIST)[13]. Furthermore, it has been reported that CT-
based morphological CT criteria have a significant asso-
ciation with pathologic response and OS in patients with
colorectal liver metastases treated with bevacizumab[11].
Functional imaging modalities like positron emission
tomography (PET)/CT that focus on metabolic para-
meters such as glucose consumption, also provide reli-
able parameters for tumor response assessment[1417].
However, although PET/CT is helpful in tumor response
assessment, standardization is still a partly insufficient
and there is limited availability in some countries.
The aim of this study was to evaluate the prognostic
value of a variety of different morphological CT measure-
ment parameters for response assessment after initiation
of chemotherapy in patients with synchronous colorectal
cancer liver metastases at initial staging.
Materials and methods
Patients
Fifty-five patients (35 men, 20 women, median age 64
years, range 3084 years) with colorectal carcinoma and
synchronous hepatic metastases on initial staging CT
were evaluated retrospectively at 2 academic centers
(Lucerne Cantonal Hospital, Switzerland and National
University Hospital, Singapore). In all patients, the pri-
mary tumor was verified by biopsy/surgery. Liver metas-
tases were diagnosed by imaging. In questionable lesions,
an additional biopsy was taken to confirm the presence of
liver metastases. A total of 150 lesions were analyzed.
For inclusion in the study, there had to be at least 1
liver metastasis, and no surgery or additional radiother-
apy was allowed until the second CT. All patients
received the same groups of chemotherapeutic sub-
stances according to the National Comprehensive
Cancer Network (NCCN) clinical practice guidelines in
oncology[9]. The chemotherapy schemes applied were
FOLFOX/CapeOx (5-fluorouracil, leucovorin, and oxali-
platin), XELOX (capecitabine and oxaliplatin), XELIRI
(capecitabine and irinotecan), or FOLFIRI (5-fluoroura-
cil, leucovorin, and irinotecan), partly together with
either bevacizumab or cetuximab. The second CT was
scheduled after 3 cycles of CapeOx, or after up to 6
cycles of FOLFIRI or FOLFIRI due to shorter chemo-
therapy intervals.
This retrospective study was approved by the institu-
tional review boards of both institutions, and by the can-
tonal ethics committee.
CT
CT scans were performed with a Somatom Definition
scanner, Somatom Definition Flash scanner, Sensation
16 scanner (Siemens Healthcare, Forchheim, Germany),
or LightSpeed VCT scanner (GE Healthcare, Fairfield,
USA). All CT scans were standard abdominal staging
CT scans with intravenous application of 80ml or 100ml
(depending on body weight) of non-ionic iodinated
contrast medium (Ultravist 370mg/ml, BayerSchering
Healthcare, Leverkusen, Germany; Omnipaque 350mg/
ml, GE Healthcare, Fairfield, CT, USA). The scan delay
was 4560 s. CT scans were performed as monophasic
scanning in portal venous phase at a tube current of
up to 168mAs and an effective tube voltage of up to
120 kV. Collimation was between 128 0.6mm and
16 1.5mm. Image reconstruction was performed with a
512 512 pixel matrix.
Data analysis
All measurements were done manually on commercial
PACS workstations (Merlin Diagnostic Workcenter,
Ph€onix-PACS, Freiburg, Germany; GE Centricity
RA1000, GE Healthcare, Fairfield, CT, USA) by 2 radi-
ologists. The reconstructed slice thickness was 3mm or
less for lesion evaluation, and 7mm or less for liver volu-
metry. The reconstruction increment was 0.8 to 2.5mm
for lesion evaluation, and 2.5 to 7mm for liver volumetry.
The liver volume was measured by manually drawing a
region of interest (ROI) around the contour of the liver
on each axial slice that displayed liver tissue. Three types
of parameters were determined for each lesion at each
time point, i.e. on baseline CT and second CT: size para-
meters, ratios, and attenuation parameters.
Size parameters were: the maximum diameter of the
largest lesion in 1 plane (meaning the longest cross-sec-
tional dimension (max1D)); the product of the 2 maxi-
mum diameters of the largest lesion in 2 planes (max2D);
the product of the 3 maximum diameters of the largest
lesion in 3 planes (max3D); the sum of the longest dia-
meters (SLD) of the 2 largest target lesions (RECIST 1.1
criteria[10]); the volume of the largest lesion, which
was determined according to the method used for liver
volumetry described above. Volumetric ratio parameters
were the tumor-to-liver-ratio (TTLR) of the 3 largest
(TTLRthree) and of all lesions (TTLRall). Attenuation
parameters as minimum, mean, and maximum
Hounsfield units (HUmin, HUmean, and HUmax) of the 3
largest lesions were measured by manually drawing an
ROI around the margin of each lesion in each axial
slice that displayed the lesion. Radiodensity
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measurements of every slice were then combined for each
lesion. All of those parameter types have already been
shown to be useful in different tumor measurement
scenarios[11,1822]. Absolute and percentage changes in
all parameters were calculated for each patient. A picto-
rial overview of the parameters is given in Fig. 1.
For all patients, the OS was identified. Time to pro-
gression (TTP), or progression-free survival, as a reflec-
tion of only the first treatment schedule, could be
identified for 31 patients. A patients disease was
regarded as progressive if there was evidence of clinical
progression. This was determined by the treating oncol-
ogist, based on a combination of clinical and imaging
information. Imaging progression on second CT or sub-
sequent examinations was defined if a radiologist
reported a progress of disease according to generally
accepted tumor response guidelines such as RECIST,
e.g. growth of the primary tumor, growth of known
metastases, or formation of new metastases.
Statistical analysis
For statistical analysis, the baseline CT parameters
(max1D, max2D, max3D, SLD, and volume) were
divided into 3 groups: small, medium and large lesions;
medium lesions were defined as being within the range of
20% of the median value. Baseline attenuation para-
meters (HUmin, HUmean and HUmax) were also split
into 3 groups; intermediate attenuation was also defined
as being within 20% of the median value. Baseline ratio
parameters TTLRthree and TTLRall were grouped logarith-
mically with intermediate ratios being defined as between
Figure 1 Parameters determined on baseline CT and second CT. Maximum diameter of the largest lesion in 1 plane
(max1D) (mm) (a); product of the 2 maximum diameters of the largest lesion in 2 planes (max2D) (mm2) (b); product of
the 3 maximum diameters of the largest lesion in 3 planes (max3D) (mm3) (c); sum of the maximum diameters (SLD) of
the 2 largest lesions (RECIST 1.1 criteria) (mm) (d); volume of the largest lesion (mm3) (e); minimum, mean, and
maximum Hounsfield units (HUmin, HUmean, and HUmax) of the 3 largest lesions (f); tumor-to-liver-ratio (TTLR) of the 3
largest (TTLRthree) and of all lesions (TTLRall) (%) (g).
CT in response evaluation for metastatic colorectal cancer 3
0.05 (5%) and 0.005 (0.5%). These thresholds were
found to work best for creating groups as evenly distrib-
uted as possible.
All follow-up results were again divided into 3 groups:
stable, progressive, and partial response. Size parameters
except volume were defined as progression if they
increased by 20% or more, and as partial response if
they decreased by 30% or more, based on the RECIST
guidelines. Volume was defined as stable if change was
within 65% to þ44%[18,19,21,23]. Follow-up ratio para-
meters TTLRthree and TTLRall were regarded as stable if
change was between 25% and þ5%. Attenuation para-
meters were defined as stable if change was between
10% and þ10%. This cutoff was derived statistically.
Regarding TTP and OS, the prognostic value of all
baseline measurements and the prognostic value of the
change between baseline and second CT measurements
were determined using hazard ratios with 95% confidence
intervals (95% CI) and KaplanMeier estimates. Survival
curves were compared using the log rank (MantelCox)
test. A P value of50.05 was considered statistically sig-
nificant. The software used was IBM SPSS StatisticsTM
19.0.1 (SPSS Inc., Chicago, IL, USA).
Results
Patients
The start of chemotherapy was after a mean period of
38 days (range 1214 days) after baseline CT. The
median CT interval was 101 days (range 42435 days).
The second CT was carried out after a median period of
63 days (range 28351 days) after the start of chemo-
therapy. Median clinical follow-up was 727 days (range
982123 days). Twenty-nine patients (53%) had died by
the end of the follow-up period, all due to progression of
their disease. All but 1 patient showed progression of
disease. Median TTP was 279 days, median OS was
704 days. Forty-four of 55 patients underwent surgery
of their primary tumor confined to the current clinical
stage during the course of the disease. The remaining
11 patients were not eligible for major surgery at the
time of diagnosis. Median OS and TTP in patients
who underwent surgery differed from that of patients
without surgery (median OS/TTP with surgery 759/220
days; median OS/TTP without surgery 561/311 days).
According to the histopathologic results, 15 of these
patients had a T4 tumor, 28 patients had a T3 tumor,
and one patient had a T2 tumor. Thirty-nine patients
showed regional lymph node metastases (19 patients
N2, 20 patients N1). The remaining 5 patients did not
show evidence of regional lymph node involvement. The
remaining 11 patients had not been treated surgically.
Baseline values
Overall, the values of the parameters determined on
baseline and second CT are shown in Table 1. All size
measurements decreased considerably from baseline to
second CT, but attenuation parameters HUmax and
HUmean only showed only a marginal reduction. None
of the parameters analyzed on the initial staging CT
had a significant correlation with OS or TTP (Table 2).
Max1D showed a tendency towards a better prognosis
for smaller lesions and a worse prognosis for larger
lesions (Fig. 2), although all 3 groups were progressive
after a similar span of time. However, this was not sta-
tistically significant. Parameters max2D and max3D
exhibited similar values (graphs not shown). There was
Table 1 Results of both CT scans: mean parameters with
95% confidence intervals (CI)
Parameters Baseline CT Second CT
Max1D (mm) 46.3 (36.855.7) 36.2 (28.643.7)
Max2D (mm2) 2919 (1420.4418) 1776 (9532599)
Max3D (mm3) 231650 (44582418716) 101126 (30788171465)
SLD/RECIST
1.1 (mm)
74.5 (59.689.4) 57.6 (45.270.0)
Volume (mm3) 185342 (14458356223) 78314 (27670128958)
TTLRthree (%) 6.28 (2.969.60) 3.77 (1.735.81)
TTLRall (%) 9.66 (5.9713.35) 5.86 (3.308.42)
HUmax 126.5 (116.4136.6) 113.1 (102.5123.6)
HUmean 68.2 (62.973.6) 59.8 (54.864.8)
HUmin 7.9 (-1.417.1) 10.4 (2.218.5)
Table 2 Baseline CT parameters: P values of log rank test and hazard ratios (HR) with 95% confidence intervals (CI)
Parameters P values of log rank test Hazard ratios (95% CI)
OS TTP OS TTP
Max1D (mm) 0.21 0.74 1.006 (0.9961.015) 1.013 (0.9981.029)
Max2D (mm2) 0.19 0.72 1.000 (1.0001.000) 1.000 (1.0001.000)
Max3D (mm3) 0.21 0.39 1.000 (1.0001.000) 1.000 (1.0001.000)
SLD (mm) 0.15 0.35 1.004 (1.0001.008) 1.007 (0.9991.014)
Volume (mm3) 0.84 0.11 1.000 (1.0001.000) 1.000 (1.0001.000)
TTLRthree (%) 0.34 0.96 2.136 (0.11739.14) 342.6 (1.46680032)
TTLRall (%) 0.39 0.19 4.200 (0.33752.39) 36.51 (0.9211447)
HUmax 0.75 0.46 1.008 (0.9991.017) 0.988 (0.9741.003)
HUmean 0.81 0.13 0.991 (0.9731.009) 0.978 (0.9580.998)
HUmin 0.02 0.5 0.984 (0.9720.996) 0.993 (0.9811.006)
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no association between the volume of the largest liver
metastasis on the initial staging CT and OS or TTP,
although there was again a trend towards better long-
term prognosis (OS) for smaller lesions (graph not
shown). The RECIST criterion (SLD) also showed a ten-
dency towards better long-term prognosis (OS) for smal-
ler lesions, although without statistical significance.
Progression-free survival for groups evaluated with SLD
did not show any tendency (graph not shown). Hazard
ratios for all size parameters were close to 1. Despite a
slight trend, neither TTLRthree (graph not shown) nor
TTLRall (Fig. 3) had a significant correlation with OS
or TTP. The hazard ratios for these ratio parameters
were different from 1, however with very large confidence
Figure 2 Survival functions depending on baseline values of max1D (maximum diameter of the largest lesion in 1
plane). (a) OS: group 1/small lesions, n¼ 18; group 2/medium lesions, n¼ 19; group 3/large lesions, n¼ 18. (b) TTP:
group 1/small lesions, n¼ 11; group 2/medium lesions, n¼ 10; group 3/large lesions, n¼ 10.
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intervals. Attenuation of lesions at baseline imaging
revealed no concordance with prognosis, except for
HUmin (Fig. 4) which showed statistically significant cor-
relation with OS; prognosis was best for the group with
intermediate HUmin lesions, and worse for the group with
high HUmin lesions. HUmax and HUmean (graphs not
shown) had no prognostic value. Hazard ratios for all
attenuation parameters were close to 1.
Trend values
The change in the parameters between baseline CT and
second CT had no significant impact on OS or TTP
(Table 3). Patients with progressive maximum diameter
of the largest lesion (max1D, Fig. 5) had a tendency
towards longer OS, but without statistical significance.
No tendency could be seen concerning TTP. Trend
Figure 3 Survival functions depending on baseline values of TTLRall (tumor-to-liver-ratio of all lesions). (a) OS: group
1/low ratio, n¼ 12; group 2/medium intermediate ratio, n¼ 18; group 3/high ratio lesions, n¼ 25. (b) TTP: group 1/
low ratio, n¼ 5; group 2/intermediate ratio, n¼ 13; group 3/high ratio, n¼ 13.
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values of parameters max2D and max3D revealed curves
without perceptible tendencies concerning OS or TTP
(graphs not shown). The change in the volume of the
largest liver metastasis was not related to OS or TTP.
The RECIST classification also had no prognostic
effect (Fig. 6). Hazard ratios for all size parameters
were again close to 1. Neither the trend for TTLRthree
or TTLRall was related to OS or TTP (graphs not shown).
In contrast to the baseline values, hazard ratios for the
trend values were close to 1. Change in HUmax, HUmean
Figure 4 Survival functions depending on the baseline values of HUmin (minimum Hounsfield units of the 3 largest
lesions). (a) OS: group 1/low HUmin lesions, n¼ 26; group 2/intermediate HUmin lesions, n¼ 4; group 3/high HUmin
lesions, n¼ 25. (b) TTP: group 1/low HUmin lesions, n¼ 24; group 2/intermediate HUmin lesions, n¼ 1; group 3/high
HUmin lesions, n¼ 6.
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(graphs not shown) or HUmin was again not related to
OS or TTP, although there was a statistically non-signif-
icant tendency towards longer OS for patients with
increasing HUmean, and towards longer TTP for patients
with increasing HUmin (graph not shown). Hazard ratios
for all attenuation parameters were again close to 1.
Discussion
Although several studies have already investigated the
possible prognostic value of baseline CT and early
second CT in different tumor entities, no study has sys-
tematically evaluated all potential measurements in one
study in such a specific patient population.
In this selective patient population, neither a signifi-
cant prognostic value of initial baseline CT parameters
(except HUmin) nor a significant prognostic value of the
change between the baseline and the second CT measure-
ment was found.
Unidimensional parameters are readily applicable. The
current standard in assessing response of solid tumors
to oncologic therapy by CT is still RECIST[10,13].
These criteria have been developed to evaluate decrease
in tumor size after cytotoxic chemotherapy, and it has
been shown that they are limited in assessing tumor
response to biological agents, which exhibit a cytostatic
mechanism of action (e.g. bevacizumab), used for the
treatment of colorectal liver metastases[11]. In general,
targeted therapies with receptor or angiogenesis inhibi-
tory agents may lead make RECIST inappro-
priate[13,2426]. In this study, RECIST 1.1 was again
not helpful in predicting the intermediate (TTP) or
final outcome (OS) of patients treated with chemother-
apy with or without biologicals. Considering only the
longest diameter of the largest lesion (max1D) was not
useful either. However, it still showed the best P value
concerning the trend between baseline and second CT
when relating to OS, but that is probably related to the
small number of patients in certain subgroups.
In recent years, new response criteria with different
response parameters have been proposed, which are
often tumor specific or modality bound, e.g. Choi criteria
for GIST response assessment to imatinib, Cheson crite-
ria or International Working Group (IWG) criteria for
malignant lymphoma by PET/CT, MacDonald criteria
for malignant glioma by contrast-enhanced CT or mag-
netic resonance imaging (MRI), and different other cri-
teria for malignant pleural mesothelioma and bone
tumors[2732]. With the increasing use of imaging to eval-
uate an increasing number of therapeutic options, these
various response parameters have contributed to rising
concern about the general sensitivity of conventional
tumor response criteria[13,16,33].
This is partly in line with our results because the atten-
uation criteria HUmean showed a trend towards better
TTP when measured at baseline, and HUmin at baseline
was the only parameter found to be statistically signifi-
cant when correlating with OS. Hazard ratios for these
parameters at baseline and second CT were close to 1, so
any prognostic value is excluded.
Volumetric measurement traditionally played a minor
role in tumor response evaluation due to its time-consum-
ing evaluation. With the introduction of digital PACS
workstations and automated volume calculation pro-
grams, volumetry became more interesting, but still
needs additional software resources. Intraindividual com-
parisons between RECIST and volumetric data revealed
differences[21,34,35] regarding tumor response evaluation
with partial advantages for volumetric measurements.
A three-dimensional quantification of lesion volume
or organ-based tumor load leads to less abstractions
than a simplified evaluation according to RECIST or
WHO[18,21,36]. In our study, the baseline volume of the
largest lesion showed a (partial) correlation with TTP.
More simplified two- (max2D) and three-dimensional
data (max3D) were also not helpful. But with hazard
ratios close to 1 for both baseline and second CT
values, these parameters have to be omitted. Even com-
plex volumetry of the 3 largest (TTLRthree) and of all
lesions (TTLRall) related to the liver volume was of no
significance, although it has been shown to be useful in
patients with hepatocellular carcinoma[22]. Thus, even
the most summarizing morphological parameter, i.e. rel-
ative tumor load shrinkage, was not associated with
Table 3 Trend CT parameters: P values of log rank test and hazard ratios (HR) with 95% confidence intervals (CI)
Parameters P values of log rank test Hazard ratios (95% CI)
OS TTP OS TTP
Max1D (mm) 0.12 0.91 0.739 (0.2751.981) 1.414 (0.3845.207)
Max2D (mm2) 0.33 0.47 0.848 (0.4851.482) 1.388 (0.6013.207)
Max3D (mm3) 0.67 0.76 0.911 (0.7071.174) 1.236 (0.6202.464)
SLD/RECIST 1.1 (mm) 0.78 0.76 0.832 (0.4011.724) 1.372 (0.3954.762)
Volume (mm3) 0.68 0.91 0.910 (0.7301.136) 1.139 (0.7021.848)
TTLRthree (%) 0.66 0.91 0.946 (0.8181.094) 1.116 (0.7361.693)
TTLRall (%) 0.58 0.91 0.974 (0.9081.045) 1.036 (0.7061.522)
HUmax 0.61 0.40 0.983 (0.9661.001) 1.004 (0.9881.020)
HUmean 0.68 0.79 0.984 (0.9631.005) 0.993 (0.9611.025)
HUmin 0.83 0.16 0.989 (0.9701.010) 0.986 (0.9651.008)
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prolonged OS or progression-free survival rates. It is obvi-
ous that the dimensions of a tumor may not accurately
reflect its intrinsic biological activity, as has been shown
for GIST treated with imatinib[13].
Recently, other morphology-based CT criteria have
been proposed for tumor response assessment[11,13,37].
Among them are the definition of lesion margins,
homogeneity of lesions, and total and relative attenua-
tion of lesions. Tumor radiodensity parameters do not
play a role in traditional tumor response assessment.
Like size measurements, they are readily applicable
and, other than margins or homogeneity, can be quan-
tified objectively and may be measured on images in
clinical routine[13]. It is believed that a decrease in
Figure 5 Survival functions depending on trend values of max1D (maximum diameter of the largest lesion in 1 plane).
(a) OS: group 1/regressive lesions, n¼ 20; group 2/stable lesions, n¼ 28; group 3/progressive lesions, n¼ 7. (b) TTP:
group 1/regressive lesions, n¼ 12; group 2/stable lesions, n¼ 15; group 3/progressive lesions, n¼ 4.
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density of responding lesions reflects necrosis, cystic or
myxoid degeneration, or decreased perfusion[13,38].
That might be a possible explanation why Hounsfield
units at least partly seem to have correlations with
outcome. However, it is still controversial if the
extent of necrosis in liver metastases in relation to
the surrounding tumor tissue increases or decreases
after the initiation of chemotherapy[39,40]. In addition,
morphological changes to hepatic tissue caused by che-
motherapeutic agents, such as steatosis or sinusoid
obstruction, may lead to an underestimation of
metastases[37,41].
Figure 6 Survival functions depending on trend values of SLD (sum of the longest diameters) of the 2 largest lesions
(RECIST 1.1). (a) OS: group 1/partial response (PR), n¼ 23; group 2/stable disease (SD), n¼ 22; group 3/progres-
sive disease (PD), n¼ 10. (b) TTP: group 1/partial response (PR), n¼ 13; group 2/stable disease (SD), n¼ 13; group
3/progressive disease (PD), n¼ 5.
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Although baseline HUmin was of statistical significance
concerning OS, we cannot exclude that this is due to the
small number of individuals in some of the subgroups
analyzed. With a more homogeneous distribution of indi-
viduals, no statistical significance has been observed for
HUmin trend. Another study focusing on neoadjuvant
treatment of colorectal liver metastases also found no
differences in density before and after chemotherapy[37].
The reason why we did not observe any impact of the
parameters analyzed on clinically relevant end points
such as OS and TTP is probably a change in therapy
respecting the results of the second CT scans. CT reports
state if there is progressive, stable or remittent disease,
according to established response assessment criteria
such as RECIST. These measurements support therapeu-
tic decisions and therapy is adapted accordingly. For
colorectal liver metastases, there are several chemother-
apeutic options available, which are given as palliative
second and third line treatments. Hence, if therapy is
changed, the statistical impact of the baseline measure-
ments and of the follow-up trends on OS might be lost.
Thus, baseline CT and second CT data may not deliver
sufficient prognostic information, at least not for OS
since TTP represents only a single treatment schedule.
Other clinical studies evaluating liver metastases from
GIST might not have been subjected to such course of
therapy because no appropriate second-line therapy was
available at that time[13]. While the introduction of ima-
tinib, and later sutinib, as second-line treatment had a
highly positive impact on GIST therapy[42], such devel-
opments are still to come for colorectal liver metastases.
On the other hand, there are promising combined che-
motherapeutic options for these lesions. New treatment
strategies for colorectal liver metastases, comprising tar-
geted drugs with biological mechanisms, may further-
more accentuate the need for new response criteria[43].
Besides CT-based morphological criteria, quantifiable
metabolic criteria from PET/CT imaging (standardized
uptake value (SUV)max) are reliable parameters for tumor
response assessment[1417]. Morphological changes of
tumors may occur late in the course of treatment, while
metabolic changes happen within a few hours[43,44],
which already may give an indication of prognosis.
However, PET/CT scanners are not as widely available
as CT scanners, and patients with newly diagnosed color-
ectal cancer usually are not evaluated primarily by PET/
CT.
Limitations
Our study has several limitations. The study design was
retrospective and the study cohort was relatively small,
although highly specific. Partly different treatment sche-
dules were applied within the range of international
guidelines for advanced CRC. While none of the 55
patients was lost to follow-up, the exact date of progres-
sion was available only from 31 patients. Hence, survival
curves for all parameters were similar concerning TTP
and OS, with the exception of the inequality of HUmin
levels on baseline CT.
Since the inclusion criterion was synchronous hepatic
colorectal metastasis, lesions were partly heterogeneous
in shape, size and number, ranging from a few well-
defined small metastases to many large metastases with
ill-defined borders. The time when patients are initially
diagnosed with hepatic metastases is often not related to
the course of these lesions themselves, but to the size and
local effects of the primary tumor, e.g. large bowel
obstruction, or might be completely coincidental.
Furthermore, a few patients also had lung metastases
and/or advanced nodal stage. The relevance of the differ-
ent OS and TTP in surgical versus non-surgical patients
remains unclear, as the patient count in the non-surgical
group was too small.
Another limitation was the partly unequal distribution
of the groups for the statistical analysis. However,
generally accepted limits of grouping for volumetry and
uni- and bidimensional measurements have been used,
if available. Furthermore, the time until the start of che-
motherapy was variable, because some patients had to
undergo emergency surgery of the primary tumor, and
post-operative worsening of their clinical condition
made a prompt initiation of chemotherapy impossible.
But these delays are common problems in clinical rou-
tine, and the second CT was performed after 3 cycles of
chemotherapy anyway.
Outlook
Novel targeted therapy regimens with receptor inhibitory
drugs or antiangiogenic agents may lead to more effec-
tiveness, and to additional inappropriateness of the tra-
ditional RECIST-based decision making. For example, it
has been shown that epidermal growth factor receptor
(EGFR) as well as k-ras mutations are negative predictive
factors for treatment response, and BRAF mutations are
negative predictive factors for survival in patients with
colorectal cancer[4548]. Thus, future chemotherapeutic
regimens may obviate traditional response assessment
criteria and emphasize the need for new predictive and
probably combined morphological and metabolic ima-
ging criteria.
Conclusion
Initial morphological response assessment using different
CT measurements and the assessment of the incipient
change in these parameters had (almost) no statistically
significant prognostic value concerning TTP and OS in
patients with synchronous colorectal liver metastases.
The possible reason might be that several consecutive
therapy lines with different chemotherapy classes are
used. Complex morphological imaging criteria do not
perform better than standard criteria used in daily rou-
tine. Hence, morphological imaging criteria might be
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used for evaluation of the current disease status but not
for predicting the final outcome in this selective patient
population. The conclusion of this study is partly limited
by the somewhat diverse patient group. Further studies
might be needed to determine if there is a predictive
morphological and measurable parameter in a larger
group of patients.
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